“April 2017 : Intensification of the Company’s international development with the appointment of a new CEO : Mrs Nawal Ouzren”
“Sensorion aims to become a major player in the development of inner ear disease treatments of and thus fulfill unmet medical needs”
"Our mission is to develop innovative and targeted treatments for inner ear diseases with vertigo, tinnitus, hearing loss"
" Sensorion, has received “French Tech Pass” certification, and thus joins an exclusive circle of innovative French technology companies with substantial development potential"

Stock information

Shareholding structure (at September 30, 2016)

 bourseEN2016 09 30

Sensorion stock

ISIN Code: FR0012596468
Mnemonic: ALSEN
Stock Market: Alternext Paris
Stock Price: click here.


Analyst coverage


Arnaud Guérin - Portzamparc


Mickael Dubourd - Aurgalys